Everest medicines announces that spero therapeutics entered into licensing agreement with pfizer inc. for spr206 in ex-u.s. and ex-asia territories

Shanghai, july 5, 2021 /prnewswire/ -- everest medicines (hkex 1952.hk), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in greater china and other parts of asia, today announced that spero therapeutics, inc. (nasdaq: spro), a licensing partner of everest medicines, entered into a regional licensing agreement with pfizer inc. (nyse: pfe) for spr206, spero's intravenously (iv)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (mdr) gram-negative infections in the hospital setting.  under the terms of the licensing agreement, spero has granted pfizer the rights to develop, manufacture, and commercialize spr206 in ex-u.s. and ex-asia territories.
SPRO Ratings Summary
SPRO Quant Ranking